TSTickerStarGet alerts

NXL 10-Q filed 2026-11-12 | Key takeaways

NXL filed its 10-Q; the most relevant disclosure change is expanded Going concern: Company disclosed substantial doubt about its ability to continue as a going concern as of September 30, 2026, with cash and cash equivalents of $793,000, working capital deficit of $869,000, accumulated deficit of $99.9M, and cash used in operating activities.

Share this story

Key takeaways

  • Going concern: Company disclosed substantial doubt about ability to continue as going concern as of September 30, 2026, with working capital deficit of $869,000, accumulated deficit of $99.9M, and cash used in operating activities of $5.1M for nine months ended September 30, 2026.

  • Nasdaq compliance: Company regained compliance with minimum bid price requirement on September 30, 2026 following one-for-thirty reverse stock split effective August 28, 2026, but must demonstrate $2.5M stockholders' equity by January 4, 2027; stockholders' equity was $263,000 as of September 30, 2026.

  • New financing: Company closed registered direct offering in August 2026 for $750K gross proceeds (80,645 shares at $9.30/share plus warrants), issued unsecured promissory note for $1.17M principal ($1M cash), and entered Any Market Purchase Agreement for up to $15M with Alumni Capital LP.

  • PONM acquisition: Company completed acquisition of PONM, Inc. on May 14, 2026 for approximately $1.3M in stock consideration to acquire licensed technology for Nexalin NeuroCare digital health platform; third tranche of 87,301 shares issued November 10, 2026.

  • Clinical trial update: Pivotal insomnia trial for HALO device initiated Q2 2026 with patient enrollment underway; clinical research organization transitioned to Curavit Clinical Research during Q3 2026.

  • New equity plan: Stockholders approved 2026 Equity Compensation Plan at August 2026 annual meeting, replacing the 2023 Plan, with up to 233,333 shares available for issuance.

  • International expansion: Company entered exclusive 10-year distribution agreement for SYNC device in Brazil and certain other Latin American markets effective September 22, 2026.

Key metrics

Total revenues - Q3 2026Q3 2026
$78,301331%
Total revenues - Nine months 2026Nine months ended September 30, 2026
$105,412-19%
Net loss - Q3 2026Q3 2026
($2,662,068)17% increase in loss
Net loss - Nine months 2026Nine months ended September 30, 2026
($6,998,075)20% increase in loss
Cash used in operating activities - Nine months 2026Nine months ended September 30, 2026
($5,102,420)34% increase in cash use
Cash and cash equivalentsSeptember 30, 2026
$793,139
Working capitalSeptember 30, 2026
($869,153) deficit
Accumulated deficitSeptember 30, 2026
$99,865,487

Disclosure changes

  • Going concern

    Company disclosed substantial doubt about its ability to continue as a going concern as of September 30, 2026, with cash and cash equivalents of $793,000, working capital deficit of $869,000, accumulated deficit of $99.9M, and cash used in operating activities of $5.1M for the nine months ended September 30, 2026.

    Going concern uncertainty indicates significant liquidity risk and substantial doubt about the company's ability to fund operations for the next twelve months.
  • Nasdaq listing compliance

    Company regained compliance with Nasdaq minimum bid price requirement on September 30, 2026 following one-for-thirty reverse stock split effective August 28, 2026; continued listing subject to demonstrating $2.5M stockholders' equity by January 4, 2027; stockholders' equity was $263,000 as of September 30, 2026.

    Delisting risk remains if company fails to meet the January 4, 2027 stockholders' equity deadline.
  • Reverse stock split

    Company effected one-for-thirty reverse stock split on August 28, 2026, reducing shares outstanding from approximately 22M pre-split to approximately 733K post-split; par value remained $0.001 per share.

    Reverse stock split increases per-share price but does not change aggregate value; reduces share count significantly.
  • New financing arrangements

    Company closed registered direct offering ($750K gross, 80,645 shares at $9.30 plus warrants), issued unsecured promissory note ($1.17M principal, $1M cash, matures Feb 2027), and entered Any Market Purchase Agreement for up to $15M with Alumni Capital LP.

    New financing extends runway but creates debt obligations and potential dilution; AMPA availability subject to market conditions and registration effectiveness.
  • Asset acquisition - PONM, Inc.

    Company acquired PONM, Inc. on May 14, 2026 for approximately $1.3M in stock consideration (payable in four tranches) to acquire licensed software and IP for Nexalin NeuroCare digital health platform; acquired intangible asset recorded at $685,000 being amortized over 7 years.

    Acquisition adds digital health platform capability but involves contingent consideration that may vary based on stock price adjustments.
  • Equity compensation plan

    Stockholders approved 2026 Equity Compensation Plan at August 2026 annual meeting, replacing the 2023 Plan, with up to 233,333 shares available for issuance; 2023 Plan awards continue under original terms.

    New equity plan provides capacity for future equity grants but with significantly reduced share pool compared to prior plan.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow NXL in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert